盐酸氢吗啡酮(Hydromorphone Hydrochloride) - 药物靶点：μ opioid receptor_在研适应症：重度疼痛，癌症疼痛，疼痛_专利_临床

The purpose of this study is to investigate the efficacy of three different modalities of post-operative pain control in parturient with opioid use disorders. The investigators aim to determine whether the different approach utilized show better outcomes with pain management and if there are any association with reduction of symptoms of anxiety, depression, and overall well-being.

开始日期2025-01-01

申办/合作机构

Medical College of Wisconsin

ChiCTR2400094277

/ SuspendedN/AIIT

Efficacy and safety analysis of hydromorphone combined with propofol intravenous anesthesia in elderly patients with PVP/PKP: a single-center clinical observational study

开始日期2025-01-01

申办/合作机构-

ChiCTR2400094749

/ Suspended早期临床1期

Effect of hydromorphone combined with ropivacaine epidural administration on traction response during cesarean section: a prospective double-blind randomized controlled trial

开始日期2025-01-01

申办/合作机构-

100 项与盐酸氢吗啡酮相关的临床结果

登录后查看更多信息

100 项与盐酸氢吗啡酮相关的转化医学

登录后查看更多信息

100 项与盐酸氢吗啡酮相关的专利（医药）

登录后查看更多信息

3,465

项与盐酸氢吗啡酮相关的文献（医药）

2025-02-01·PLANT CELL AND ENVIRONMENT

Multi‐Omics Analysis Reveals Molecular Responses of Alkaloid Content Variations in Lycoris aurea Across Different Locations

Article

作者: Deng, Hong‐Ping ; You, Shi‐Qi ; Zhang, Xiao ; Quan, Miao‐Hua ; Peng, Yang ; Liu, Guang‐Hua ; Zuo, You‐Wei ; Long, Na‐Na

ABSTRACT:

Lycoris aurea, celebrated for its visually striking flowers and significant medicinal value due to the presence of alkaloids such as lycorine and galanthamine, has intricate yet poorly understood regulatory mechanisms. This study provides a detailed examination of the transcriptomic, metabolomic and ecological dynamics of L. aurea, aiming to elucidate the underlying molecular mechanisms of alkaloid biosynthesis. Our comparative analysis across different ecological settings highlighted key genes involved in alkaloid biosynthesis, such as genes encoding aldehyde dehydrogenase and norbelladine 4′‐O‐methyltransferase, which were distinctively increased in the high alkaloids‐producing group. We identified a total of 6871 differentially expressed genes and 915 metabolites involved in pathways like terpenoid backbone biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis. Protein interaction network analysis revealed significant upregulation of photosynthesis, photosystem and photosynthetic membrane pathways in the alkaloids‐producing region. Furthermore, our research delineated the interactions among soil microbial communities, genes and plant and soil biochemical properties, noting that bacterial populations correlate with soil properties that favour the activation of metabolic pathways essential for alkaloid production. Collectively, this study advances our understanding of the genetic and metabolic alkaloid biosynthesis pathways in L. aurea, shedding light on the complex interactions that govern alkaloid production.

2025-01-01·Drug testing and analysis

Plasma drug screening using paper spray mass spectrometry with integrated solid phase extraction

Article

作者: Ren, Greta ; Dowling, Sarah ; Rusyniak, Daniel ; Warren, Cassandra ; Manicke, Nicholas E. ; Zimmerman‐Federle, Hannah ; Avera, Robert

Abstract:

Drug overdoses have risen dramatically in recent years. We developed a simple nontargeted method using a disposable paper spray cartridge with an integrated solid phase extraction column. This method was used to screen for ~160 fentanyl analogs, synthetic cannabinoids, other synthetic drugs, and traditional drugs of abuse in over 300 authentic overdose samples collected at emergency departments in Indianapolis. A solid phase extraction step was implemented on the paper spray cartridge to enable subnanograms per milliliter synthetic drugs screening in plasma. Analysis was performed on a quadrupole orbitrap mass spectrometer using the sequential window acquisition of all theoretical fragment ion spectra approach in which tandem mass spectrometry was performed using 7 m/z isolation windows in the quadrupole. Calibration curves with isotopically labeled internal standards were constructed for 35 of the most frequently encountered synthetic and traditional illicit drugs by US toxicology labs. Additional qualitative‐only drugs in a suspect screening list were also included. Limits of detection in plasma for synthetic cannabinoids ranged from 0.1 to 0.5 and 0.1 to 0.3 ng/mL for fentanyl and its analogs and between 1 and 5 ng/mL for most other drugs. Relative matrix effects were evaluated by determining the variation of the calibration slope in 10 different lots of biofluid and found to be between 3% and 20%. The method was validated on authentic overdose samples collected from two emergency departments in Indianapolis, Indiana, from suspected or known overdoses. Commonly detected synthetic drugs included fentanyl related substances, designer benzodiazepines such as flubromazolam, and the synthetic cannabinoid 5F‐PB‐22.

2025-01-01·VETERINARY ANAESTHESIA AND ANALGESIA

Effects of hydromorphone alone and combined with medetomidine-vatinoxan or dexmedetomidine on alfaxalone induction dose and mean arterial pressure in dogs anesthetized with sevoflurane

Article

作者: Zhu, Xiaojuan ; Seddighi, Reza ; Bussières, Genevieve ; Kleine, Stephanie A ; Hampton, Chiara E ; Smith, Christopher K ; Davis, Lily V

OBJECTIVE:

To evaluate the dose of alfaxalone needed for induction of anesthesia following sedation with medetomidine-vatinoxan plus hydromorphone (MVH), dexmedetomidine plus hydromorphone (DH), or hydromorphone (H) alone. A secondary objective included evaluating selected cardiopulmonary variables before, during, and after sedation and general anesthesia with sevoflurane in healthy dogs.

STUDY DESIGN:

Prospective, randomized, masked, crossover.

ANIMALS:

Eight healthy Beagle dogs, 3-4 years old.

METHODS:

All dogs received three intramuscular (IM) treatments: H (0.1 mg kg^-1), DH (0.005 mg kg^-1 + 0.1 mg kg^-1, respectively), or MVH (0.01 mg kg^-1 + 0.2 mg kg^-1 + 0.1 mg kg^-1, respectively) at least 6 days apart. General anesthesia was induced with alfaxalone 20 minutes after treatment administration and maintained for 60 minutes with 2.8% sevoflurane (expired). Sedation scores, selected cardiopulmonary variables, and recovery scores were measured before, during, and after anesthesia at selected timepoints. Mixed-effects ANOVA and ANOVA on ranks were used to evaluate differences between treatments, time, and their interaction, and Tukey-Kramer method was used for post hoc analysis (p < 0.05). Data are presented as mean ± SD or median (range).

RESULTS:

Dogs given MVH required a lower dose of alfaxalone for induction of anesthesia (0.77 ± 0.4 mg kg^-1) compared to DH and H (1.16 ± 0.34 mg kg^-1; p = 0.02, 1.13 ± 0.18 mg kg^-1; p = 0.02), and had a higher incidence (50%; p = 0.038) and longer duration [median; 10 (0-35) minutes] of hypotension during sevoflurane anesthesia compared to H [0%; 0 (0-0) minutes; p = 0.040] but not DH (p = 0.272).

CONCLUSIONS AND CLINICAL RELEVANCE:

Premedication with MVH provided the greatest alfaxalone-sparing effect. However, this treatment was associated with lower arterial pressures and clinically relevant hypotension. Off-label use of medetomidine-vatinoxan before sevoflurane-based anesthesia should be used with caution due to a high incidence of hypotension.

119

项与盐酸氢吗啡酮相关的新闻（医药）

2025-01-25

·赛柏蓝

央企入主后，这家龙头药企更换董事长

作者 | 颜色来源 | 赛柏蓝人福医药刚迎来央企入主，又更换董事长。 01 人福医药董事长换人 1月25日，人福医药发布《关于董事长辞职及选举新任董事长暨变更法定代表人的公告》，因工作调整，李杰辞去董事长和法定代表人职务。同时，人福医药选举董事周汉生为董事长。周汉生既是人福医药董事及下属部分控股子公司董事，也是武汉当代科技产业集团董事。武汉当代科技产业集团曾是人福医药的控股股东，9天之前，人福医药发布公告称，控股股东签署重整投资协议。招商局创新科技（集团）成为重整投资人，参与当代科技本次重整，投资总额为118亿元。招商创科通过全资设立的招商局生命科技（武汉）参与当代科技的重整，并将控制当代科技持有的人福医药23.7%的股票表决权，成为人福医药新的控股股东。 “麻醉一哥”刚迎来央企控股随即更换董事长。同日，人福医药董事会秘书李前伦因工作调整辞去董事会秘书职务，继续担任副总裁及公司下属子公司其他职务。在董事会秘书空缺期间，暂由董事、总裁邓霞飞代行董事会秘书的职责。李杰在人福医药已经工作4年多，2020年4月3日，人福医药选举李杰担任第九届董事会董事长。李杰历任宜昌市化工医药局技术科科长、湖北宜药集团总经理、董事长、党委书记等。 2021年-2024年前三季度，人福医药实现营收205.49亿元、223.38亿元、245.25亿元、191.43亿元，同比增长-0.63%、8.71%、9.79%、5.70%；实现净利润13.17亿元、24.84亿元、21.34亿元、15.90亿元，同比增长30.96%、88.60%、-14.07%、-10.12%。 2023年-2024年前三季度，人福医药增收不增利。从人福医药2023年年报和2024年半年报来看，其营收成本、销售费用、管理费用、财务费用、研发费用相较同期均有所上涨。对于管理费用的变化，人福医药称与员工薪酬、差旅费用增长和固定资产折旧增加相关。人福医药2023年年报人福医药2024年半年报作为“麻醉一哥”的人福医药，需要寻求更多刺激利润增长的落脚点。 02 业务调整，下一步发展？招商创科对人福医药的重整被业内视为人福医药接下来发展的“定心丸”，在医药细分领域处于领先地位的人福医药，招商创科入主后，有望增强综合竞争力。人福医药拥有市场上不少重磅产品，尤其在国内神经系统用药、甾体激素类药物、维吾尔民族药等细分领域。米内网数据显示，2023年中国公立医疗机构终端麻醉剂化药的销售规模超过200亿元，2024年上半年人福医药以35亿元的销售额排在Top 1集团，市场份额升至34.84%。凭借芬太尼系列产品，如枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸阿芬太尼注射液等，人福医药与恒瑞医药、恩华药业并称麻醉药领域的三大龙头。人福医药子公司宜昌人福的芬太尼系列、氢吗啡酮等产品为国家管制类药品，具有极强的专业性和较高的行业壁垒。不过，2023年，枸橼酸舒芬太尼注射液、盐酸阿芬太尼注射液的销售量比上年均有所减少，分别减少1.37%、21.59%。 2023年人福医药营业收入或毛利的10%以上的产品，或营业收入、毛利排名前5的产品，以及重点细分领域的主要产品近年来行业监管趋严，药品入院难度加大，叠加医保基金控费等因素影响，产品销售不及预期的风险有所增加。 2024年半年报中，人福医药提出，积极推进“归核聚焦”工作，持续优化资产业务。在取得阶段性进展的基础上，继续清理竞争优势不明显或协同性较弱的资产。人福医药正在推进武汉康乐药业、湖北人福成田药业、人福大成（武汉）投资管理有限公司等公司股权的出售工作。同时，围绕既定细分领域进行产品业务的布局拓展，不断提高市场竞争力。人福医药于2017年提出“归核聚焦”战略，并于2018年开始清理竞争优势不明显，协同性较弱的资产，包括非核心医药工商业资产、医疗服务资产、部分金融资产等，优化业务及资产结构。目前，人福医药主要参股公司有8家，包括宜昌人福、葛店人福、武汉人福、Epic Pharma、新疆维药、三峡制药、北京医疗、湖北人福。人福医药2024年半年报 2024年上半年，宜昌人福实现营收45.02亿元，同比增长11.78%，实现净利润14.25亿元，同比增长17.59%。作为人福医药的“现金奶牛”，宜昌人福的竞争力还在增加。从央企入主到董事长换人，人福医药虽然变动频频，但留给其发展的空间还很广阔。 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

高管变更财报

2025-01-21

·echemi

Humanwell Healthcare Secures Major Investment: A New Era Begins with Strategic Backing

After a three-month hiatus, leading domestic anesthetics producer Humanwell Healthcare has officially been "acquired" by a state-backed entity. On January 15, the company announced that it had signed a restructuring investment agreement with Zhaoshang Innovation Technology Group Co., Ltd. and its management team. This collaboration involves an investment of ¥11.8 billion, positioning Zhaoshang Innovation as the new controlling shareholder, with a 23.70% stake in Humanwell Healthcare. The restructuring investment will be executed in two phases. The first phase, covering 60% of the investment, will be paid upon the approval of the restructuring plan by the Wuhan Intermediate People’s Court. The remaining 40% will be paid after the completion of stock and voting rights transfers. Once this restructuring plan is finalized, Humanwell Healthcare will officially transition to state-owned control, a move that has significantly boosted its stock price, reaching ¥23.6 per share and a market capitalization of ¥38.52 billion. A Shift in Leadership: Hope for the "Anesthetic King" Founded in 1993, Humanwell Healthcare was once the dominant force in the anesthetic drugs sector. However, it has faced unprecedented challenges due to its former major shareholder, Dandai Technology, being mired in a debt crisis. Previously, six potential restructuring investors had passed the initial review, including three state-owned enterprises and three large local state-owned enterprises. Dandai Technology’s 23.7% stake in Humanwell Healthcare is currently frozen due to judicial actions. The entry of Zhaoshang Innovation brings a glimmer of hope, with the investment structured in three parts: Direct acquisition of 6% of Humanwell Healthcare’s shares. Indirect acquisition of another 6% through a new limited partnership in the Donghu New Technology Development Zone, with Zhaoshang Innovation as the general partner. Trust plan acquiring 11.70% of shares, with all voting rights delegated to Zhaoshang Innovation. Zhaoshang Innovation is controlled by China Merchants Group, a significant state-owned enterprise headquartered in Hong Kong. In 2023, China Merchants Group reported revenues of ¥924.4 billion and a net profit of ¥191.1 billion, showcasing its robust financial standing. Strategic Investment Amid Market Challenges Zhaoshang Innovation's substantial investment indicates its strategic interest in Humanwell Healthcare's industry-leading position in the pharmaceutical sector. Humanwell Healthcare is one of the few companies capable of producing a full range of fentanyl products and has established a strong foothold in various segments, including anesthetics and steroid hormones. According to the latest data, Humanwell Healthcare holds a 25.9% market share in the anesthetics market, making it the leading player. Its products, including alfentanil and hydromorphone, have a 100% market share, illustrating its dominance. In the past five years, Humanwell Healthcare has invested ¥4.6 billion in research and development, reflecting a commitment to innovation. In 2023, R&D expenses surpassed ¥1 billion, with a 9.2% increase in the first three quarters of 2024. The company has received approval for 1 traditional Chinese medicine and 17 chemical drug products, indicating a robust pipeline for future growth. Despite these positive developments, challenges remain. The competitive landscape is fierce, and the company must ensure that its R&D investments yield proportional returns. The support from Zhaoshang Innovation may provide the necessary impetus for Humanwell Healthcare to navigate these challenges successfully and emerge stronger. With Zhaoshang Innovation taking a controlling stake, Humanwell Healthcare's ownership issue has reached a significant resolution. This strategic investment from a state-owned entity sends positive signals to the market. However, the company still faces challenges related to market competition and R&D efficiency. Observers will be keen to see if Humanwell Healthcare can leverage this new partnership to overcome its obstacles and achieve a successful turnaround.

并购上市批准

2025-01-20

·ioncology

路平教授：从氢吗啡酮PCA便捷模式到氢吗啡酮缓释片，癌痛管理稳步前行，患者无痛未来可期

点击上方蓝字关注我们编者按：癌痛是肿瘤患者常见症状，严重影响患者生活质量及生存期。我国在国家政策导向、社会行业发展、医护日常工作等方方面面不断强调癌痛管理重要性，并在新药研发、癌痛管理策略方面不断优化。作为最早一批开展“癌痛规范化病房”的负责人之一、“2023-2024年推动中国肿瘤支持治疗建树奖”获得者，新乡医学院第一附属医院路平教授为癌痛管理的提升贡献了力量，不仅在2024年欧洲肿瘤内科学会亚洲会议（ESMO Asia）发布了“氢吗啡酮患者自控镇痛（PCA）10天便捷模式”用于癌痛管理的相关研究，而且正在着手开展氢吗啡酮缓释片的优化应用探索，为不断改进癌痛管理策略而深入研究。“肿瘤瞭望”特别采访路平教授，分享她所牵头的癌痛管理相关临床研究，并分享癌痛管理心得，以飨读者。 01 《肿瘤瞭望》：癌痛管理是对肿瘤患者全病程管理的重要组成部分，请您结合临床工作经验分享一下对癌痛管理的心得体会？路平教授：癌痛是肿瘤领域非常重要的话题，在即将到来的2025年春节，我团队参与的一年一度无痛过年活动将如约而至，希望能为更多癌痛患者带来获益。之所以大家非常关注癌痛，是因为癌痛作为肿瘤患者最常见的症状，会在约60%-80%的中晚期肿瘤患者中出现，不单单会影响患者的生活质量，也会影响患者的生存期。优化癌痛管理，提高患者的生活质量刻不容缓。国内外专家对癌痛都非常关注，并制定了中国临床肿瘤学会（CSCO）、美国国家癌症综合网络（NCCN）、欧洲肿瘤内科学会（ESMO）、医政医管局《癌症疼痛诊疗规范2018》等诸多国内外指南，需要我们去遵循。自我国2018年“癌痛规范化病房”建设以来，我国很多医院、医生对癌痛实现了同质化管理。我们团队十分重视癌痛管理，第一批获得“癌痛规范化病房”资质，设立了多学科团队（MDT）和院外管理的标准操作流程，从而使90%以上乃至全部患者达到无痛的状态。 02 《肿瘤瞭望》：您在所做的诸多工作为我国癌痛管理水平的提升贡献了力量，也为国际学者带来了参考。2024年您在ESMO Asia年会发布了一项关于“氢吗啡酮患者自控镇痛（PCA）10天便捷模式在重度疼痛或疼痛危象癌症患者居家管理可行性探索”的壁报，请您分享一下该研究的设计及结果。路平教授：近年来，我们团队在癌痛领域做了很多工作，我也很荣幸获得了“2023-2024年推动中国肿瘤支持治疗建树奖”，感谢广大同道对我们的肯定。 2024年ESMO Asia发布的CHASE002研究是由我院牵头，河南省16家中心共同参与的临床研究，旨在评价氢吗啡酮自控镇痛（PCA）泵10天便捷模式的止痛效果和居家便利性。该研究设立的初衷，是因为我们作为唯一一个座落于县城的省直属三级甲等教学医院，会有许多重度癌痛的终末期癌症患者前来就诊，如何让此类终末期癌症患者有尊严地离世是我们非常关注的一点，而此前内科常用的PCA泵操作模式过于复杂，我们团队以患者为中心，希望能够在癌痛管理中找到一种便捷的PCA模式，能够让医生、患者更容易操作，并能够推广出去。因此，我们设计了此项研究。开展多中心研究之前，我们对氢吗啡酮PCA简易模式进行多次优化，确立了可行性。在此基础上，我们在CHASE002研究中纳入了100例患者进行进一步验证。氢吗啡酮PCA10天便捷模式分为2个阶段，第一阶段为滴定阶段，以1.0ml/h的泵速滴定24h；第二阶段为维持阶段，将后续10天氢吗啡酮总剂量加入泵中，总量288ml，泵速1.2m/h，PCA 单次剂量（bolus dose）为2.4ml，在出现爆发痛时按压一次，可在背景剂量基础上增加0.1ml。在该模式下，结果显示滴定成功的概率达到100%，患者不良反应较轻，生活质量也得明显提高。氢吗啡酮PCA10天便捷模式使用时需要记忆的数据少，应用便捷，医生和患者都会操作。在CHASE002研究取得成功之后，参与研究的16家单位均已对适合的患者常规应用该模式。该模式确确实实是一项适宜的技术，我们已于2024年着手申请专利，并希望将该技术推广到全国，惠及更多患者。因此，我们也在牵头一项全国多中心临床研究，计划纳入50家中心，希望更多癌痛患者能够享受到该模式带来的效果，从而取得更多受益。 03 《肿瘤瞭望》：2024年盐酸氢吗啡酮缓释片的上市弥补了国内空白，请您谈谈其临床疗效及安全性表现如何？您正在开展的相关研究现阶段取得了怎样的成果？路平教授：氢吗啡酮缓释片采用了口服渗透泵缓释技术（Osmotic Release Oral System，OROS），填补了国内空白，与国外的氢吗啡酮缓释片疗效及安全性一致，得到了广泛认可。在该药的Ⅲ期临床研究中，氢吗啡酮缓释片对比羟考酮缓释片达到了非劣效研究终点，安全性方面更具有优势趋势，且每日仅需用药一次，更加便捷，患者依从性也更高。氢吗啡酮缓释片与硫酸吗啡缓释片相比，则能更大限度地降低患者疼痛评分，不良反应更轻。此外，一项随机、双盲临床研究则显示氢吗啡酮缓释片较吗啡缓释片在控制慢性疼痛方面的镇痛效果更加理想，且在改善患者日常活动、情绪、行动能力、工作、睡眠等方面均具有更好的生活质量。如今，我们正在牵头一项有关氢吗啡酮缓释片全国多中心临床研究。一方面，CHASE002研究中的氢吗啡酮PCA10天便捷模式值得向全国推广。另一方面，在对患者癌痛进行院外管理时，选择氢吗啡酮PCA泵、氢吗啡酮缓释片、羟考酮缓释片、吗啡缓释片的治疗效果如何，将对患者生活质量带来哪些影响是值得深入探索的。希望此项研究的结果在2025年公布以后，能够为患者带来更好的选择，带来更多的获益，也能够为国家相关政策的出台提供更加有力的循证医学证据。 04 《肿瘤瞭望》：日前我国医保局将国内独家新药盐酸氢吗啡酮缓释片纳入医保，对此您有怎样的评价？路平教授：在癌痛领域，人福药业提供了全面的品种，做出了巨大贡献。近年来，治疗癌痛的新药物、新剂型并不多，人福药业的氢吗啡酮缓释片的上市填补了国内空白。氢吗啡酮作为一个阿片类镇痛药物，主要作用于μ阿片受体，效力强，起效快，已经纳入了ESMO、NCCN、卫健委等多个组织的指南。氢吗啡酮缓释片上市即降价、上市即纳入医保，我相信必将为更多癌痛患者带来获益。在我们课题设计之初，氢吗啡酮缓释片的价格在900元左右，我还在想老百姓怎么能够承受得起，然而我们的卡提还未开始，其价格就已经主动降低到200多元，为患者切实带来了实惠与受益。总之，我非常感谢人福药业，也非常感谢我们的国家，让我们老百姓能够享受到如此优质、且价格相对低廉的药物，让我觉得作为中国人非常的骄傲。对于患者而言，从国家、企业到医生，方方面面都在围绕着“以患者为中心”开展诊治。我相信，将来会有越来越多的患者受益于氢吗啡酮缓释片。路平教授新乡医学院第一附属医院新乡医学院附属肿瘤医院执行院长/一附院肿瘤医院院长兼博士后工作站主任二级教授、博士、博士生导师、博士后联合导师国家临床重点专科学术带头人全国五一劳动奖章获得者/白求恩精神践行者推动中国肿瘤支持治疗建树奖获得者加拿大玛格丽特公主医院、英国皇家马斯登医院访问学者国家十三五规划教材中英文《肿瘤学》编委中国生命关怀协会肿瘤无创治疗专业委员会副主任委员中国医疗器械行业协会放射治疗专业委员会常务委员中国麻醉药品协会合理用药分会理事中国县域乳腺癌诊疗指南执笔人河南省医学会肿瘤分会副主任委员发表SCI论文50余篇，科技成果奖5项，参加国际国内合作项目200余项（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

CSCO会议

100 项与盐酸氢吗啡酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00839	盐酸氢吗啡酮	N02AA03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
重度疼痛	美国	Hikma Pharmaceuticals USA, Inc.	2023-12-14
癌症疼痛	日本	Daiichi Sankyo Co., Ltd.	2017-06-01
术后疼痛	美国	SpecGx LLC	2010-03-01
疼痛	美国	Fresenius Kabi USA LLC	1984-01-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
关节炎疼痛	临床3期	-	Mallinckrodt Plc	2008-02-01
腰痛	临床3期	-	ALZA Corp.	2006-12-13
慢性骨关节炎	临床3期	-	ALZA Corp.	2006-11-14
慢性疼痛	临床3期	美国	Purdue Pharma LP	2005-07-01
髋关节炎	临床3期	-	ALZA Corp.	2003-11-01
膝关节炎	临床3期	-	ALZA Corp.	2003-11-01
麻醉	临床3期	-	Johnson & Johnson	-
镇痛	临床2期	-	ALZA Corp.	2006-12-14
肿瘤	临床1期	中国	西安杨森制药有限公司	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04230681 (CTgov)	早期临床1期	阻塞性睡眠呼吸暂停综合征 \| 扁桃体炎	189	Hydromorphone (Hydromorphone)	齋製觸鑰築艱夢蓋蓋艱(夢網築窪夢鏇簾醖選憲) = 積齋鬱構憲鹽積選壓餘網願夢獵製鏇餘製鹽築 (簾遞蓋願鹽繭遞齋網遞, 築艱選鹹顧壓衊廠築鹹 ~ 憲鏇窪顧鬱膚願淵壓壓) 更多	-	2024-12-18
				Fentanyl (Fentanyl)	齋製觸鑰築艱夢蓋蓋艱(夢網築窪夢鏇簾醖選憲) = 憲簾鑰獵鹹構簾繭壓製網願夢獵製鏇餘製鹽築 (簾遞蓋願鹽繭遞齋網遞, 觸齋遞鹹鬱憲糧衊膚憲 ~ 醖鏇觸憲網蓋鹽願窪築) 更多
NCT05244226 (CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征 \| 扁桃体炎 \| 操作性疼痛	66	Hydromorphone+Fentanyl	蓋憲餘窪獵構鑰積廠願(構齋淵遞鏇觸鹹齋醖鏇) = 窪壓淵選簾鬱艱鹽願構構醖鏇夢醖膚積鏇構糧 (衊餘膚壓鹽網簾鑰觸築, 糧憲夢齋網鹹窪繭淵夢 ~ 艱餘製築願繭獵觸壓願) 更多	-	2024-10-17
NCT04258631 (CTgov)	临床4期	女性生殖器官肿瘤 \| 疼痛	105	Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine))	夢膚願糧膚觸築製醖簾(艱膚艱糧壓窪選鑰襯觸) = 遞積鏇鏇窪選鑰衊糧糧艱齋鹽繭觸選網壓衊遞 (襯選選醖獵窪鏇艱膚簾, 繭襯願願構廠廠淵艱齋 ~ 顧構衊網網簾鏇鹹衊積) 更多	-	2024-10-16
				Laparotomy+Hydromorphone+Liposomal Bupivacaine (Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone))	夢膚願糧膚觸築製醖簾(艱膚艱糧壓窪選鑰襯觸) = 憲窪艱製鹹鏇餘鬱簾壓艱齋鹽繭觸選網壓衊遞 (襯選選醖獵窪鏇艱膚簾, 憲糧簾鬱鑰窪壓艱觸淵 ~ 繭憲觸遞夢憲憲選鹹遞) 更多
NCT02939209 (Pubmed \| Can J Anaesth)	临床4期	-	73	Hydromorphone 2 mg	鑰膚醖夢膚鑰選簾簾鑰(壓醖繭積鹽鬱鬱壓蓋鏇) = 顧積鑰網獵廠艱顧網遞襯襯壓齋膚網淵繭廠壓 (鬱繭顧壓憲範積醖觸築, 2.4)	不佳	2024-06-01
				Placebo	鑰膚醖夢膚鑰選簾簾鑰(壓醖繭積鹽鬱鬱壓蓋鏇) = 製膚觸襯夢醖餘艱鹽鬱襯襯壓齋膚網淵繭廠壓 (鬱繭顧壓憲範積醖觸築, 2.3)
NCT04296305 (ASCO2024)	临床4期	癌症疼痛	-	IV hydromorphone 1mg over 15 minutes	構遞廠淵繭觸鑰網選構(積廠糧簾膚選遞壓願積) = Drowsiness was more frequent in the standard group than the experimental group (50% vs 29% at 15 minutes, and 52% vs 31% at 60 minutes) 鬱簾積憲範構網夢糧鏇 (鏇膚窪夢衊糧廠網鏇襯 )	积极	2024-05-24
				IV hydromorphone 1mg over 2 minutes
NCT02223377 (SAME-Day, CTgov)	N/A	镇痛 \| 术后恶心呕吐 \| 呕吐	402	Morphine (Morphine)	鹽構顧壓膚顧餘獵襯蓋(構襯齋構築繭積窪鏇夢) = 艱願願網鹹遞願窪範選鏇獵積鬱窪鬱糧糧網衊 (鏇廠繭築憲憲糧構淵觸, 積鏇鹽網鑰範艱製網糧 ~ 網積糧選簾齋鹽蓋夢廠) 更多	-	2023-12-11
				Hydromorphone (Hydromorphone)	鹽構顧壓膚顧餘獵襯蓋(構襯齋構築繭積窪鏇夢) = 網廠構構繭鑰願憲網獵鏇獵積鬱窪鬱糧糧網衊 (鏇廠繭築憲憲糧構淵觸, 齋遞獵鬱餘鏇積獵構鹹 ~ 鑰顧鹽顧憲鏇淵壓齋鬱) 更多
NCT04429022 (RA-TLH, CTgov)	临床3期	术后疼痛	68	Local anesthetic injection+Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites+Hydromorphone+Acetaminophen+Ketorolac+Celecoxib+Oxycodone+Gabapentin (Prospective Cohort)	壓獵繭膚廠遞繭憲觸簾(築艱鬱鹹廠衊餘顧鑰築) = 憲繭鹽鏇壓築襯壓觸醖憲遞簾夢憲築遞鏇鬱餘 (鬱製衊製獵蓋糧選艱製, 廠選壓衊鏇壓構願選鹹 ~ 觸製繭製鬱製醖網醖顧) 更多	-	2023-08-01
				Hydromorphone (Historical Control)	壓獵繭膚廠遞繭憲觸簾(築艱鬱鹹廠衊餘顧鑰築) = 夢積餘蓋顧築鹽繭夢餘憲遞簾夢憲築遞鏇鬱餘 (鬱製衊製獵蓋糧選艱製, 鑰簾壓淵憲蓋積齋憲鬱 ~ 鹽夢鑰觸遞鏇鑰窪醖鏇) 更多
NCT03933397 (COMPARE-VOE, CTgov)	临床3期	血管闭塞危机 \| 镰状细胞血症	328	Patient-Specific Protocol+Hydromorphone+Morphine (Patient-Specific Protocol)	蓋糧遞醖淵觸憲構構糧(鏇遞築糧構鏇築願網鹽) = 積願獵鹹膚鬱淵淵鏇襯鬱蓋網鑰淵鹹齋獵積膚 (膚壓選製窪繭範積蓋壓, 鹽齋醖夢膚觸艱鑰膚構 ~ 簾餘築鏇醖鏇獵願積醖) 更多	-	2023-07-03
				Weight-based Protocol+Hydromorphone+Morphine (Weight-based Protocol)	蓋糧遞醖淵觸憲構構糧(鏇遞築糧構鏇築願網鹽) = 範築顧遞艱範淵獵齋壓鬱蓋網鑰淵鹹齋獵積膚 (膚壓選製窪繭範積蓋壓, 範築襯積憲蓋遞觸製顧 ~ 顧艱鏇糧遞積蓋鑰廠窪) 更多
ARVO2022	N/A	MOTS-c peptide	-	MOTS-c peptide in H2O	窪膚繭築簾鏇築艱鑰廠(壓衊衊觸獵襯獵獵鏇築) = 衊選憲夢遞衊蓋獵餘選觸廠構鬱艱觸獵蓋築衊 (醖選鹽憲範顧憲窪糧淵 ) 更多	-	2022-06-01
NCT03553498 (CTgov)	临床3期	急性疼痛	162	hydromorphone+IV acetaminophen (IV Hydromorphone and IV Acetaminophen)	醖選廠衊繭鹽願醖遞選(窪網鹽餘觸膚積鹹艱顧) = 醖願糧築鹹淵鏇鬱遞齋簾壓糧製鹹窪觸齋蓋廠 (選獵鏇憲襯夢願選夢鬱, 鏇簾繭願膚齋齋廠齋選 ~ 膚遞遞淵願壓簾襯範鹽) 更多	-	2022-03-02
				IV placebo+hydromorphone (IV Hydromorphone and Placebo)	醖選廠衊繭鹽願醖遞選(窪網鹽餘觸膚積鹹艱顧) = 鬱繭餘範構選鏇鑰窪鑰簾壓糧製鹹窪觸齋蓋廠 (選獵鏇憲襯夢願選夢鬱, 夢鹽鬱製餘齋憲選淵範 ~ 積憲觸積壓壓積衊憲齋) 更多